When you ask, Who Bought Verve? you’re tapping into a fascinating story of biotech innovation, big pharma ambition, and the relentless push to make healthcare more convenient and effective.
And no—we’re not talking about the Verve Credit Card this time. That’s a different kind of Verve, the one you check through your Verve Credit Card login to manage payments and track spending. In this case, we’re diving into Verve Therapeutics—a major name in gene editing and digital health.
The recent acquisition of this cutting-edge company stands out as a prime example of how major players are betting big on the future of medicine. Let’s walk through what happened, why it matters, and what you—whether you’re an investor, a patient, or just a tech enthusiast—should take away from this headline-grabbing deal.
Who Owns Verve Now?
If you’ve been following biotech news, you know the question of Who Bought Verve? has been buzzing in industry circles. The answer: pharmaceutical giant Eli Lilly & Company has agreed to acquire Verve Therapeutics, a cutting-edge gene-editing startup, in a deal valued at up to $1.3 billion.
This isn’t just another corporate buyout—it’s a strategic move that signals where the future of cardiovascular treatment is headed.
- Eli Lilly will pay $10.50 per share in cash, with the possibility of an additional $3.00 per share if certain development milestones are met, bringing the total potential value to $13.50 per share.
- The deal represents a 113% premium over Verve’s recent average stock price, showing just how much Lilly values Verve’s technology.
- The acquisition is expected to close in the third quarter of 2025, pending regulatory approvals and the tender of a majority of Verve’s outstanding shares.
This move is all about accelerating the development of gene-editing therapies for heart disease, a market with massive unmet needs and blockbuster potential.
Why Did Eli Lilly Buy Verve?
When you dig into Who Bought Verve?, you quickly see this wasn’t just a financial play. For Eli Lilly, the acquisition is a calculated leap into the world of in vivo gene editing—specifically, therapies that could transform the way we treat high cholesterol and cardiovascular disease. Here’s why this matters:
- Verve’s lead program, VERVE-102, targets the PCSK9 gene, which is linked to cholesterol levels. The therapy aims to provide a one-and-done treatment for patients at risk of heart disease, moving away from the current model of daily pills or injections.
- The U.S. FDA has granted Fast Track designation to VERVE-102, highlighting its potential to address serious unmet medical needs.
- For Lilly, this acquisition fits into a broader strategy to expand its portfolio in genetic medicines and cardiovascular care, complementing its strengths in diabetes and metabolic disease.
Let’s be honest: the promise of a single-dose, gene-editing cure for heart disease is the kind of moonshot that could change millions of lives—and make billions for whoever gets there first. No wonder Lilly was willing to pay a hefty premium.
How the Verve Acquisition Happened?
In the world of mergers and acquisitions, the details matter. When you ask Who Bought Verve?, you’re also asking how the deal was structured and what it means for stakeholders. Here’s the breakdown:
| Buyer | Target Company | Deal Value (Upfront) | Potential Total Value | Payment Structure | Key Milestone for Extra Payment | Expected Closing |
|---|---|---|---|---|---|---|
| Eli Lilly | Verve Therapeutics | $1.0 billion | $1.3 billion | $10.50/share cash + $3.00/share CVR | First patient dosed with VERVE-102 in U.S. Phase 3 trial | Q3 2025 |
- The deal includes a non-tradeable Contingent Value Right (CVR), which rewards shareholders with extra cash if Verve hits a key clinical milestone: dosing the first patient with VERVE-102 in a U.S. Phase 3 trial within ten years of closing.
- If not all shares are tendered in the initial offer, Lilly will use a second-step merger to acquire any remaining shares at the same price.
- The deal has been unanimously recommended by Verve’s board and already has support from key shareholders representing about 17.8% of the company.
As someone who’s watched plenty of pharma deals come and go, I can tell you: this structure is designed to align everyone’s interests and keep the focus on clinical progress.
What Does This Mean for Patients and Investors?
For those wondering who bought Verve and why it matters to them, let’s get practical. This deal isn’t just about boardrooms and balance sheets—it has real-world implications.
- Patients with high cholesterol or genetic risk for heart disease could soon have access to a transformative therapy that might eliminate the need for lifelong medication.
- Investors in Verve saw a big payday, with the buyout price representing a massive premium over recent trading levels.
- For Eli Lilly shareholders, the acquisition is a bold bet on the future of gene editing—one that could pay off handsomely if VERVE-102 and other pipeline candidates succeed.
Of course, there’s risk here. Gene-editing therapies face tough regulatory scrutiny, and clinical milestones are never guaranteed. But if you’re looking for a textbook example of how big pharma is embracing disruptive tech, this is it.
Conclusion
To wrap up, when people ask Who Bought Verve?, the answer is clear: Eli Lilly & Company made a major move to acquire Verve Therapeutics, betting up to $1.3 billion on the promise of gene-editing therapies for cardiovascular disease. This isn’t just a headline for Wall Street—it’s a signal that the future of medicine is arriving faster than ever.
If you want to keep up with these trends, use platforms like this one to track deals, dig into company pipelines, and stay ahead of the curve. Got more questions about biotech, investing, or the next big thing in health tech? I’m here to walk you through it—just ask!
